Bonraybio CoTPE:6955 65 Return-on-Tangible-Equity is 19.77% as of Dec. 2025, which is 261% above its 10-year median of 5.47. GuruFocus rates TPE:6955 with a GF Score™ of 65/100 and a GF Value™ of NT$184.74 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Bonraybio Co ranks better than 81.29% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bonraybio Co's annualized net income for the quarter that ended in Dec. 2025 was NT$119.3 Mil. Bonraybio Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$603.2 Mil. Therefore, Bonraybio Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 19.77%.
The historical rank and industry rank for Bonraybio Co's Return-on-Tangible-Equity or its related term are showing as below:
TPE:6955'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -44.88 Med: 5.47 Max: 17.84
Current: 17.84
During the past 6 years, Bonraybio Co's highest Return-on-Tangible-Equity was 17.84%. The lowest was -44.88%. And the median was 5.47%.
TPE:6955's Return-on-Tangible-Equity is ranked better than 81.29% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.07
vs TPE:6955: 17.84
Bonraybio Co (TPE:6955) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bonraybio Co Return-on-Tangible-Equity Related Terms
Bonraybio Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bonraybio Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6955 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Bonraybio Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonraybio Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonraybio Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bonraybio Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 19.77% mean?
Bonraybio Co (TPE:6955) has a Return-on-Tangible-Equity of 19.77% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bonraybio Co and its competitors. This is 261% above median its historical median of 5.47. According to the industry distribution chart, Bonraybio Co ranks #142 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 18.7%.
Is Bonraybio Co's Return-on-Tangible-Equity too high?
Bonraybio Co's current Return-on-Tangible-Equity of 19.77% is 261% above median its 10-year median of 5.47. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.07. Bonraybio Co's value of 19.77% is 385.7% above this industry median. Based on the distribution chart, Bonraybio Co ranks #142 out of 759 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bonraybio Co has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonraybio Co's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bonraybio Co ranks #142 out of 759 companies for Return-on-Tangible-Equity. This places Bonraybio Co in the top 19% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.07. Bonraybio Co's value of 19.77% is 385.7% above this benchmark. While the company's 10-year median is 5.47 vs. the industry median of 4.07, Bonraybio Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.07, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonraybio Co's current Return-on-Tangible-Equity of 19.77% is 385.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bonraybio Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonraybio Co's current Return-on-Tangible-Equity is 19.77%, which is 261% above median its own 10-year median of 5.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonraybio Co stock overvalued right now?
Based on GuruFocus' analysis, Bonraybio Co (TPE:6955) is currently considered Possible Value Trap. The stock's GF Value™ is NT$184.74, compared to a current price of NT$120.50 — trading 34.8% below its estimated fair value. The current Return-on-Tangible-Equity is 19.77%, which is 261% above median its 10-year median of 5.47 and 385.7% above the Medical Devices & Instruments industry median of 4.07. Bonraybio Co's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bonraybio Co (TPE:6955), the current Return-on-Tangible-Equity is 19.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonraybio Co (TPE:6955) Overvalued in 2026?
Based on GuruFocus' analysis, Bonraybio Co stock appears to be undervalued.
The current stock price of NT$120.50 is trading 34.8% below its estimated GF Value™ of NT$184.74.
GuruFocus considers Bonraybio Co to be Possible Value Trap.
Key valuation signals for TPE:6955:
Return-on-Tangible-Equity: 19.77% (261% above median its 10-year median of 5.47)
GF Value™: NT$184.74 vs. price of NT$120.50 (34.8% below fair value)
Industry Position: 385.7% above the Medical Devices & Instruments median (#142 of 759)
No single metric tells the full story. See the TPE:6955 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonraybio Co Ltd engages in research, development, and manufacturing of vitro diagnostic devices. The firm produces semen quality analyzers and Semen Analysis Systems for the clinic.
65GF Score
Get the complete analysis for TPE:6955
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6955 has been successfully added to your 
